<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04844749</url>
  </required_header>
  <id_info>
    <org_study_id>V3011102</org_study_id>
    <nct_id>NCT04844749</nct_id>
  </id_info>
  <brief_title>Efficacy Evaluation of VERU-111 for mCRPC in Patients Who Have Failed at Least One Androgen Receptor Targeting Agent</brief_title>
  <acronym>VERACITY</acronym>
  <official_title>VERACITY - Randomized, Active-Controlled, Phase 3 Study of VERU-111 for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Who Have Failed Prior Treatment With at Least One Androgen Receptor Targeting Agent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Veru Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Veru Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To demonstrate the efficacy of VERU-111 (Sabizabulin) in the treatment of metastatic&#xD;
      castration-resistant prostate cancer in patients who have failed prior treatment with at&#xD;
      least one androgen receptor targeting agent as measured by radiographic progression-free&#xD;
      survival.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multicenter, randomized, open-label, active-control, efficacy and safety&#xD;
      study of VERU-111 (Sabizabulin) for the treatment of metastatic castration-resistant prostate&#xD;
      cancer in patients who have failed prior treatment with at least one androgen receptor&#xD;
      targeting agent.&#xD;
&#xD;
      Subjects will have failed treatment with at least one prior androgen receptor targeting agent&#xD;
      and be eligible for treatment with an alternative androgen receptor targeting agent (as per&#xD;
      the current standard of care for these patients).&#xD;
&#xD;
      Subjects will be randomized in a 2:1 ratio to receive VERU-111 or Active Control (alternative&#xD;
      androgen receptor targeting agent).&#xD;
&#xD;
      Subjects in the VERU-111 treated group will receive VERU-111 32 mg per day orally with an&#xD;
      option to reduce the dose to 26 mg per day based on tolerability to the 32 mg dose until&#xD;
      radiographic progression (blinded independent central read) in observed. Subjects in the&#xD;
      Control treated group will receive an alternative androgen receptor targeting agent with dose&#xD;
      and dosing regimen defined in the FDA approved prescribing information until radiographic&#xD;
      progression in observed.&#xD;
&#xD;
      Randomization will be stratified by measurable disease vs. bone-only disease. A significant&#xD;
      proportion (&gt;30%) of the patients randomized into the study will have measurable disease at&#xD;
      baseline.&#xD;
&#xD;
      Randomization will also be stratified by if the patient has failed one vs. more than one&#xD;
      prior androgen targeting agent.&#xD;
&#xD;
      The primary efficacy endpoint of the study will be radiographic progression free survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 24, 2021</start_date>
  <completion_date type="Anticipated">August 19, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 29, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This randomized, open-label, active-control clinical study consists of two treatment arms:VERU-111 (Sabizabulin) treated group, and Control treated group. Subjects will be randomized in a 2:1 fashion.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Central reader for scans will be blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of VERU-111 in the treatment of metastatic castration-resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent</measure>
    <time_frame>360 days</time_frame>
    <description>Radiographic progression-free survival (rPFS) centrally read, which is death or tumor progression as defined by RECIST 1.1 (soft tissue) and PCWG3 (bone).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>360 days</time_frame>
    <description>Overall survival (OS) will be an assessment of time from randomization into the study to all-cause mortality. The analysis will be performed similarly to the primary endpoint.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">245</enrollment>
  <condition>Metastatic Castration-resistant Prostate Cancer</condition>
  <condition>Androgen Resistant Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>32mg of VERU-111 26mg of VERU-11</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active control alternative androgen receptor targeting agent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The alternative androgen receptor targeting agent will be administered according to the dosing instructions in the current product prescribing information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VERU-111</intervention_name>
    <description>Based on the safety and antitumor activity of VERU-111 in the Phase 1b/2 clinical study, VERU-111 is initiating this Phase 3 clinical study of VERU-111 for the treatment of metastatic castration resistant prostate cancer in patients who have failed prior treatment with at least one androgen receptor targeting agent</description>
    <arm_group_label>Either VERU-111 32mg or 26mg dose will be supplied as capsules 1 orally once a day</arm_group_label>
    <other_name>Sabizabulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide, Abiraterone, Darolutamide and Apalutamide</intervention_name>
    <description>Enzalutamide and abiraterone were chosen as active comparators are both are FDA approved for the treatment of metastatic castration resistant prostate cancer</description>
    <arm_group_label>Active control alternative androgen receptor targeting agent</arm_group_label>
    <other_name>XTANDI</other_name>
    <other_name>Zytiga</other_name>
    <other_name>Nubeqa</other_name>
    <other_name>Erleada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide informed consent.&#xD;
&#xD;
          -  Be able to communicate effectively with the study personnel.&#xD;
&#xD;
          -  Aged ≥18 years.&#xD;
&#xD;
          -  Histological or cytologic proof of adenocarcinoma of the prostate not including the&#xD;
             diagnosis of small cell carcinoma of the prostate of neuroendocrine pathology.&#xD;
&#xD;
          -  Radiographic evidence of metastatic disease at baseline by CT scan, or MRI and bone&#xD;
             scan, with confirmation of measurable disease by RECIST 1.1 and/or identifiable&#xD;
             discrete bone metastases by PCWG3.&#xD;
&#xD;
          -  Known castration resistant prostate cancer, defined according to PCWG3 criteria.&#xD;
&#xD;
          -  Have received at least one androgen receptor targeting agent (e.g. abiraterone,&#xD;
             enzalutamide, darolutamide, or apalutamide).&#xD;
&#xD;
          -  Subjects who have metastatic castration resistant prostate cancer that have maintained&#xD;
             ADT and have failed prior treatment with at least one androgen receptor targeting&#xD;
             agent (abiraterone,enzalutamide, darolutamide, or apalutamide) defined as:&#xD;
&#xD;
          -  Serum PSA progression of two consecutive increases in PSA over a previous reference&#xD;
             value within 6 months of first study treatment, each measurement at least 2 weeks&#xD;
             apart. Or&#xD;
&#xD;
          -  Documented bone lesions by the appearance of two or more new lesions on bone&#xD;
             scintigraphy or bi-dimensionally-measurable soft tissue metastatic lesion assessed by&#xD;
             CT or MRI.&#xD;
&#xD;
          -  Treatment with an alternative androgen receptor targeting agent is a reasonable next&#xD;
             line of therapy.&#xD;
&#xD;
          -  Absolute PSA ≥2.0 ng/ml at screening.&#xD;
&#xD;
          -  ECOG performance status &lt;2.&#xD;
&#xD;
          -  Participants must have normal organ and bone marrow function measured within 30 days&#xD;
             prior to administration of study treatment as defined below:&#xD;
&#xD;
          -  Hemoglobin ≥9.0 g/dL with no blood transfusion in the past 30 days&#xD;
&#xD;
          -  Creatinine clearance ≥60 mL/min&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) ≥1.5 x 109/L&#xD;
&#xD;
          -  Platelet count ≥100 x 109/L&#xD;
&#xD;
          -  Total bilirubin ≤ upper limit of normal (ULN) (or &lt;2.5 x ULN for patients with known&#xD;
             Gilberts disease)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (Serum Glutamic Oxaloacetic Transaminase&#xD;
             (SGOT))/Alanine aminotransferase (ALT) (Serum Glutamic Pyruvate Transaminase (SGPT))&#xD;
             ≤2.5 x ULN. NOTE: Patients with elevations in bilirubin, AST, or ALT should be&#xD;
             thoroughly evaluated for the etiology of this abnormality prior to entry and patients&#xD;
             with evidence of viral infection should be excluded. Patients with chronic renal stent&#xD;
             and stable creatinine elevation can be included in the study with written&#xD;
             documentation from the PI.&#xD;
&#xD;
          -  Participants must have a life expectancy &gt;3 months.&#xD;
&#xD;
          -  Subjects must agree to use acceptable methods of contraception:&#xD;
&#xD;
          -  If the study subject's partner could become pregnant, use acceptable methods of&#xD;
             contraception from the time of the first administration of study medication until&#xD;
             6months following administration of the last dose of study medication. Acceptable&#xD;
             methods of contraception are as follows: Condom with spermicidal&#xD;
             foam/gel/film/cream/suppository [i.e.,barrier method of contraception], surgical&#xD;
             sterilization (vasectomy with documentation of azospermia) and a barrier method&#xD;
             {condom used with spermicidal foam/gel/film/cream/suppository}, the female partner&#xD;
             uses oral contraceptives (combination estrogen/progesterone pills), injectable&#xD;
             progesterone or subdermal implants and a barrier method (condom used with spermicidal&#xD;
             foam/gel/film/cream/suppository).&#xD;
&#xD;
          -  If female partner of a study subject has undergone documented tubal ligation (female&#xD;
             sterilization), a barrier method (condom used with spermicidal&#xD;
             foam/gel/film/cream/suppository)should also be used.-If female partner of a study&#xD;
             subject has undergone documented placement of an intrauterine device (IUD) or&#xD;
             intrauterine system (IUS),a barrier method (condom with spermicidal&#xD;
             foam/gel/film/cream/suppository)should also be used.&#xD;
&#xD;
          -  Other than metastatic prostate cancer, no evidence (within 5 years) of prior&#xD;
             malignancies (except successfully treated basal cell or squamous cell carcinoma of the&#xD;
             skin or other cancers treated with curative intent &gt;3 years prior).&#xD;
&#xD;
          -  Participants must agree to refrain from prolonged exposure to the sun or agree to use&#xD;
             at least SPF 50 on all exposed skin and protective clothing during prolonged sun&#xD;
             exposure throughout participation in this study and/or treatment with VERU- 111.&#xD;
&#xD;
          -  Subject is willing to comply with the requirements of the protocol through the end of&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known hypersensitivity or allergy to colchicine.&#xD;
&#xD;
          -  Histologic identification of small cell carcinoma of the prostate or neuroendocrine&#xD;
             pathology in either biopsy or prostatectomy tissue.&#xD;
&#xD;
          -  A bone scan with evidence of superscan or superscan phenomenon, defined as:&#xD;
&#xD;
          -  Uptake throughout the axial skeleton and proximal appendicular skeleton, often&#xD;
             somewhat heterogeneous, or,&#xD;
&#xD;
          -  Symmetrically intense and diffuse radiotracer uptake in the skeleton with absent or&#xD;
             diminished visualization of the genitourinary system and soft tissues, or,&#xD;
&#xD;
          -  Defined in the bone scan report as a superscan or superscan phenomenon. NOTE: Medical&#xD;
             Monitor should be consulted prior to screening of a patient if a superscan or&#xD;
             superscan phenomenon is suspected or possible, but undetermined by any of the above&#xD;
             definitions.&#xD;
&#xD;
          -  Has received external-beam radiotherapy within the last 2 weeks prior to start of&#xD;
             study treatment.&#xD;
&#xD;
          -  Patients with a QT interval corrected by Fridericia's formula of &gt;480 ms.&#xD;
&#xD;
          -  Patients receiving full dose warfarin therapy are not eligible for study.&#xD;
&#xD;
          -  Patients with prior history of a thromboembolic event within the last 6 months.&#xD;
&#xD;
          -  Participation in another clinical study with an investigational product during the&#xD;
             last 6 months prior to randomization into this study.&#xD;
&#xD;
          -  Patients should be excluded if they have had prior systemic treatment with prior&#xD;
             taxane chemotherapies (for greater than 2 cycles) for advanced prostate cancer.&#xD;
             Patient can have up to 2 cycles of prior taxane chemotherapy greater than one year&#xD;
             prior to randomization and remain eligible for inclusion in this study. Taxane&#xD;
             exposure in the adjuvant or neoadjuvant setting is allowed (maximum of 6 cycles).&#xD;
&#xD;
          -  Any treatment modalities involving major surgery within 4weeks prior to the start of&#xD;
             study treatment.&#xD;
&#xD;
          -  Patients are excluded if they have known brain metastases or leptomeningeal&#xD;
             metastases.&#xD;
&#xD;
          -  Patients should be excluded if they have a positive test for hepatitis B virus surface&#xD;
             antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating&#xD;
             acute or chronic infection.&#xD;
&#xD;
          -  Has imminent or established spinal cord compression based on clinical findings and/or&#xD;
             MRI.&#xD;
&#xD;
          -  Any other serious illness or medical condition that would, in the opinion of the&#xD;
             investigator, make this protocol unreasonably hazardous. Active infections discovered&#xD;
             during screening period must be treated and controlled before patient is dosed with&#xD;
             VERU-111.&#xD;
&#xD;
          -  Persistent toxicities (&gt;Common Terminology Criteria for Adverse Event (CTCAE) grade 2)&#xD;
             caused by previous cancer therapy, excluding alopecia.&#xD;
&#xD;
          -  Poor medical risk due to a serious, uncontrolled medical disorder, non-malignant&#xD;
             systemic disease or active, uncontrolled infection. Examples include, but are not&#xD;
             limited to, uncontrolled ventricular arrhythmia, recent (within 6 months) myocardial&#xD;
             infarction, uncontrolled major seizure disorder, extensive interstitial bilateral lung&#xD;
             disease, or any psychiatric disorder that prohibits obtaining informed consent.&#xD;
&#xD;
          -  Total bilirubin levels &gt; 1.5 x ULN (&gt;2.5 x ULN in patients with known Gilbert's&#xD;
             disease).&#xD;
&#xD;
          -  AST and/or ALT levels &gt;2.5xULN or AST and/or ALT levels &gt;1.5xULN WITH concomitant&#xD;
             alkaline phosphatase levels &gt;2.5xULN.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barnette</last_name>
    <role>Study Chair</role>
    <affiliation>Veru Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barnette</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rodriguez</last_name>
    <phone>800-606-9382</phone>
    <email>veruclinicaltrials@verupharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Oncology and Hematology, LLC.</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashli Meek</last_name>
      <phone>907-257-9851</phone>
      <email>ashli@alaskaoncology.com</email>
    </contact>
    <investigator>
      <last_name>Steven Lui</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Urology Specialists - Glendale- Arrowhead</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gladis Solis</last_name>
      <phone>602-734-0309</phone>
      <email>gsolis@arizonauro.com</email>
    </contact>
    <investigator>
      <last_name>Roscoe Nelson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates of Southern Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85715</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Montijo</last_name>
      <phone>520-351-5582</phone>
      <email>christinam@uasapc.com</email>
    </contact>
    <investigator>
      <last_name>Susan Kalota</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Institute of Urology</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucy Pena</last_name>
      <phone>520-784-7087</phone>
      <email>lpena@aiurology.com</email>
    </contact>
    <contact_backup>
      <last_name>Crystal Placencia</last_name>
      <phone>520-784-7019</phone>
      <email>cplacencia@aiurology.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kalpesh Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Urology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie O'Brien</last_name>
      <phone>501-219-8900</phone>
      <email>katie@arkansasurology.com</email>
    </contact>
    <investigator>
      <last_name>Jeff Marotte</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tower Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terry Williams</last_name>
      <phone>310-854-9898</phone>
      <phone_ext>178</phone_ext>
      <email>williamst@towerurology.com</email>
    </contact>
    <investigator>
      <last_name>David Josephson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California, Irvine</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Bereta</last_name>
      <phone>714-456-8148</phone>
      <email>sbereta@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Edward Uchio</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Coaster Center Urology</name>
      <address>
        <city>Oxnard</city>
        <state>California</state>
        <zip>93036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paola Martinez</last_name>
      <phone>520-351-5583</phone>
      <email>pmartinez@fomatmedical.com</email>
    </contact>
    <contact_backup>
      <last_name>Lorenzo Aguirre</last_name>
      <phone>(520) 351 5583</phone>
      <email>laguirre@fomatmedical.com</email>
    </contact_backup>
    <investigator>
      <last_name>Sherif Aboseif</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Bernardino Urological Associates</name>
      <address>
        <city>San Bernardino</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roxie Miller</last_name>
    </contact>
    <investigator>
      <last_name>Franklin Chu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Genesis Resaerch, LLC</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonia Romo</last_name>
      <phone>858-430-1101</phone>
      <email>sromo@genhp.com</email>
    </contact>
    <investigator>
      <last_name>Paul Dato</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alicia Buenrostro</last_name>
    </contact>
    <investigator>
      <last_name>Richard David</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Colorado Urology</name>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <zip>80401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Aggers</last_name>
      <phone>303-996-9649</phone>
      <email>daggers@coloradouro.com</email>
    </contact>
    <investigator>
      <last_name>David Cahn</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universal Axon Clinical Research</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Benitez</last_name>
      <phone>305-677-9267</phone>
      <phone_ext>19</phone_ext>
      <email>abenitez@uaclinical.com</email>
    </contact>
    <investigator>
      <last_name>Luis Martinez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mike Cusnir</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Urology</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Joseph Festa</last_name>
      <email>jfesta@advancedurology.com</email>
    </contact>
    <investigator>
      <last_name>Vahan Kassabian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Idaho Urologic Institute, PA</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Misty Pichardo</last_name>
      <phone>208-639-4946</phone>
      <email>mpichardo@idurology.com</email>
    </contact>
    <investigator>
      <last_name>John Greer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Stroger Jr. Hospital of Cook County</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Courtney Hollowell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Urologic Care</name>
      <address>
        <city>Lake Barrington</city>
        <state>Illinois</state>
        <zip>60010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacqueline Bueno</last_name>
      <phone>847-852-7906</phone>
      <email>jbueno@compurocare.com</email>
    </contact>
    <investigator>
      <last_name>Ning Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Urology, PSC</name>
      <address>
        <city>Jeffersonville</city>
        <state>Indiana</state>
        <zip>47130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Nessel</last_name>
      <phone>812-206-8162</phone>
      <email>cnessel@1sturology.com</email>
    </contact>
    <investigator>
      <last_name>James Bailen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Regional Urology, LLC</name>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <zip>71106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Renfro</last_name>
      <phone>318-683-0411</phone>
      <phone_ext>125</phone_ext>
      <email>lrenfro@regionalurology.com.com</email>
    </contact>
    <investigator>
      <last_name>Ralph Henderson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Biesecker</last_name>
      <phone>443-471-5750</phone>
      <email>cbiesecker@chesuro.com</email>
    </contact>
    <investigator>
      <last_name>Ronald Tutrone</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Michigan Institute of Urology</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48084</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Danielle Osterhoutd</last_name>
      <phone>248-786-0467</phone>
      <email>osterhoutd@michiganurology.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Kernan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MidAmerica Cancer Care</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jaswinder Singh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GU Research Network, LLC</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Mittelstedt</last_name>
      <phone>402-991-8468</phone>
      <email>hmittelstedt@gucancer.com</email>
    </contact>
    <investigator>
      <last_name>Luke Nordquist</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inpsira Medical Center Mullica Hill</name>
      <address>
        <city>Mullica Hill</city>
        <state>New Jersey</state>
        <zip>08062</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shanta Salzer</last_name>
    </contact>
    <investigator>
      <last_name>Erev Tubb</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inspira Medical Center</name>
      <address>
        <city>Vineland</city>
        <state>New Jersey</state>
        <zip>08360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mylene Go</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension - Our Lady of Lourdes Memorial Hospital</name>
      <address>
        <city>Binghamton</city>
        <state>New York</state>
        <zip>13905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Kathleen McGinley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12603</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Crespi</last_name>
      <phone>845-437-5010</phone>
      <email>lcrespi@premiermedicalhv.com</email>
    </contact>
    <investigator>
      <last_name>Evan Goldfischer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of NY, PLCC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Faisal</last_name>
      <phone>315-478-4185</phone>
      <phone_ext>7794</phone_ext>
      <email>sfaisal@ampofny.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Pieczonka</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Associated Urologists of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kip Moffett</last_name>
      <phone>919-390-7368</phone>
      <email>kmoffett@auncurology.com</email>
    </contact>
    <investigator>
      <last_name>Mark Jalkut</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Moshe Ornstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions - Cleveland</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kalapis</last_name>
      <phone>440-340-9010</phone>
      <email>jkalapis@crssites.com</email>
    </contact>
    <investigator>
      <last_name>Lawrence Gervasi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Urology Institute</name>
      <address>
        <city>Springfield</city>
        <state>Oregon</state>
        <zip>97477</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Kerns</last_name>
      <phone>541-284-5508</phone>
      <email>stephanie@oregonurology.com</email>
    </contact>
    <investigator>
      <last_name>Bryan Melhaff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centers for Advanced Urology, LLP MidLantic Urology</name>
      <address>
        <city>Bala-Cynwyd</city>
        <state>Pennsylvania</state>
        <zip>19004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittny Goodell</last_name>
      <phone>610-667-0458</phone>
      <email>bgoodell@midlanticurology.com</email>
    </contact>
    <investigator>
      <last_name>Laurence Belkoff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kate Valipour</last_name>
      <phone>843-449-1010</phone>
      <phone_ext>268</phone_ext>
      <email>kvalipour@curcmb.com</email>
    </contact>
    <investigator>
      <last_name>Neal Shore</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lexington Medical Center/ Lexington Oncology</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taylor Knight</last_name>
      <phone>803-794-7511</phone>
      <email>tvknight@lexhealth.org</email>
    </contact>
    <contact_backup>
      <last_name>Selena Lollar</last_name>
      <phone>803-794-7511</phone>
      <email>swlollar@lexhealth.org</email>
    </contact_backup>
    <investigator>
      <last_name>Steven Madden</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates - Nashville</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Morris</last_name>
      <phone>615-622-5017</phone>
    </contact>
    <investigator>
      <last_name>David Morris</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Houston Metro Urology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rezwana Zahir</last_name>
      <phone>281-912-5762</phone>
      <email>rezwana.zahir@hmutx.com</email>
    </contact>
    <investigator>
      <last_name>Zvi Schiffman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology San Antonio P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pankaj Aggarwal</last_name>
      <phone>210-617-4116</phone>
      <email>pankaj.aggarwal@urologysa.com</email>
    </contact>
    <investigator>
      <last_name>Daniel Saltzstein</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Devitt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Urology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brittany Quigley</last_name>
      <phone>804-288-2785</phone>
      <phone_ext>7802</phone_ext>
      <email>bpquigley@uro.com</email>
    </contact>
    <investigator>
      <last_name>Eugene Kramolowsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology of Virginia, PLLC</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23462</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Robert Given</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Spokane Urology P.S.</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Bardwell</last_name>
      <phone>509-747-3147</phone>
      <email>AmyB@spokaneurology.com</email>
    </contact>
    <investigator>
      <last_name>Raymond Lance</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Prostatic Neoplasms, Castration-Resistant</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

